Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Karyopharm Therapeutics Climbed Today

By Cory Renauer - Updated Apr 13, 2019 at 6:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were pleased with the company's latest presentation.

What happened

Shares of Karyopharm Therapeutics (KPTI 9.07%), a clinical-stage biopharmaceutical business, rose 12.7% on Monday after investors had a chance to digest the company's latest investor presentation. Those still holding out hope for Karyopharm's lead candidate, selinexor, gave the stock its lift today.

So what 

Karyopharm has a couple of new drug candidates in early-stage testing, but selinexor for multiple myeloma is the only one close to the finish line. Last month, the stock tanked after an independent advisory panel voted 8 to 5 in favor of pausing selinexor's FDA review until results from an ongoing phase 3 study become available near the end of the year.

Check out the latest earnings call transcript for Karyopharm Therapeutics.

Man in a suit drawing an upward-sloping chart with his fingers.

Image source: Getty Images.

Last week, the Food and Drug Administration announced it would delay completing its review from April 6 to July 6. Investors didn't quite know what to make of the FDA's decision, because the phase 3 trial the agency wants to see complete data from isn't going to wrap up until the end of the year at the earliest.

Earlier today, the company presented its plan for selinexor, and despite a lack of new details, investors found it encouraging.

Now what

The FDA's decision to extend its review of selinexor for the treatment of multiple myeloma patients who have failed three prior lines of treatment probably isn't a positive sign. According to Karyopharm, the agency delayed the application in order to review additional clinical data the company had submitted. Delays of this sort aren't unusual, but all they really tell you is that the company didn't get it right the first time.

Those hoping the delay is a sign that the FDA hasn't already made up its mind will probably be disappointed. The FDA noted 10 fatal treatment-emergent events among just 123 patients in the Storm study, while only 25% of the group showed response to treatment. While a delay is better than a complete response letter, the odds of an approval based on the risk-to-benefit ratio for selinexor are not good.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Karyopharm Therapeutics Inc. Stock Quote
Karyopharm Therapeutics Inc.
$5.41 (9.07%) $0.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.